Karmanos Cancer Hospital
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230297
- Received
- $5,691,545 in 1,135 records, 2022 ($102,276 general, $5,589,268 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 13 | $102,276 |
| 2022 | Research payment | 1,122 | $5,589,268 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,122 | $5,589,268 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $65,684 |
| Space rental or facility fees (teaching hospital only) | 7 | $36,500 |
| Debt forgiveness | 1 | $92 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $92,341 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $63,372 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab MK-7684 with Pembrolizumab M | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $56,944 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $45,677 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $28,472 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $27,336 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $21,354 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $21,234 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $16,574 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $15,082 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $14,788 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,032 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,681 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $11,642 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,562 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $8,776 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,603 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,496 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,172 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,825 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,709 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,655 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,139 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,860 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,274 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,820 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,794 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,387 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,360 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,246 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,125 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,555 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,466 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,431 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,892 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,840 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,545 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,290 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,023 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $1,010 | Research payment | In-kind items and services | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $517 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $364 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $227 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib Trial of Pembrolizumab MK-3475 in Combination with Dinaciclib MK-7965 in Subjects with Hematologic Malignancies | 2022 |
| 2022-12-29 | TRILLIUM THERAPEUTICS USA, LLC | $8,266 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2022 | |
| 2022-12-29 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | Drug | LIGHT CHAIN AMYLOIDOSIS REAL WORLD EVIDENCE RWE CONSORTIUM LARC | 2022 |
| 2022-12-28 | Daiichi Sankyo Inc. | $2,500 | Research payment | Cash or cash equivalent | DS1062-A-U301 | 2022 | |
| 2022-12-28 | BeiGene, Ltd. | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho | 2022 | |
| 2022-12-28 | Daiichi Sankyo Inc. | $500 | Research payment | Cash or cash equivalent | ENHERTU Drug, ONCOLOGY | DS-8201-A-U204 | 2022 |
| 2022-12-28 | Regeneron Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2022 | |
| 2022-12-27 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | LUNSUMIO Biological, BioOncology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-26 | Janssen Research & Development, LLC | $858 | Research payment | Cash or cash equivalent | A Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub | 2022 | |
| 2022-12-26 | Janssen Research & Development, LLC | $858 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit | 2022 | |
| 2022-12-22 | Alkermes, Inc. | $38,025 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2022 | |
| 2022-12-22 | Aveo Pharmaceuticals, Inc. | $14,000 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-22 | Aveo Pharmaceuticals, Inc. | $4,760 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-22 | Aveo Pharmaceuticals, Inc. | $2,040 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-22 | Aveo Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-22 | Aveo Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-22 | Aveo Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-22 | SANOFI US SERVICES INC. | $1,500 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver | 2022 |
| 2022-12-22 | SANOFI US SERVICES INC. | $1,500 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver | 2022 |
| 2022-12-22 | SANOFI US SERVICES INC. | $1,320 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver | 2022 |
| 2022-12-22 | Aveo Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-22 | Regeneron Pharmaceuticals, Inc. | $645 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2022 | |
| 2022-12-22 | Bayer Healthcare Pharmaceuticals Inc. | $418 | Research payment | Cash or cash equivalent | Xofigo Drug, Oncology | Long Term follow up with Xofigo | 2022 |
| 2022-12-22 | SEAGEN INC. | $300 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-CD70 in Myeloid Malignancies | 2022 | |
| 2022-12-22 | SANOFI US SERVICES INC. | $158 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Ver | 2022 |
| 2022-12-21 | Genentech, Inc. | $8,533 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | A PHASE II STUDY EVALUATING SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB | 2022 |
| 2022-12-21 | Celgene Corporation | $1,890 | Research payment | Cash or cash equivalent | (CC-92480-MM-002) Phase IIA - DMCP Managed Basket Trial | 2022 | |
| 2022-12-19 | Merck Sharp & Dohme LLC | $18,498 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2022 |
| 2022-12-19 | Janssen Research & Development, LLC | $16,120 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2022 |
| 2022-12-19 | Genentech, Inc. | $8,140 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2022 |
| 2022-12-19 | Janssen Research & Development, LLC | $4,939 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2022 |
| 2022-12-19 | Janssen Research & Development, LLC | $2,386 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-12-19 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-12-19 | Janssen Research & Development, LLC | $260 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-12-19 | Janssen Research & Development, LLC | $68 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $2,926 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $2,774 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $2,697 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-16 | Janssen Research & Development, LLC | $72 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-15 | Novocure Inc. | $1,500 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2022 | |
| 2022-12-15 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2022 | |
| 2022-12-15 | EMD Serono, Inc. | $500 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-12-15 | EMD Serono, Inc. | $476 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-12-14 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | TIVDAK Biological, Oncology | Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o | 2022 |
| 2022-12-14 | Genentech, Inc. | $1,428 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2022 |
| 2022-12-13 | Genentech, Inc. | $8,886 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-13 | Genentech, Inc. | $8,539 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-13 | Genentech, Inc. | $6,121 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-13 | Genentech, Inc. | $1,320 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-13 | Genentech, Inc. | $1,320 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-13 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-13 | Janssen Research & Development, LLC | $573 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2022 |
| 2022-12-13 | Janssen Research & Development, LLC | $530 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2022 |
| 2022-12-12 | Genentech, Inc. | $30,672 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2022 |
| 2022-12-12 | Janssen Research & Development, LLC | $6,200 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-12-09 | National Marrow Donor Program | $13,500 | Research payment | Cash or cash equivalent | A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplant | 2022 | |
| 2022-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $200 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2022 | |
| 2022-12-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $73,449 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | malignant pleural mesothelioma US | 2022 |
| 2022-12-08 | EMD Serono, Inc. | $5,465 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-12-08 | Regeneron Pharmaceuticals, Inc. | $4,541 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2022 | |
| 2022-12-08 | Alkermes, Inc. | $1,064 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2022 | |
| 2022-12-07 | Gilead Sciences, Inc. | $3,339 | Research payment | Cash or cash equivalent | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-P | 2022 | |
| 2022-12-07 | Gilead Sciences, Inc. | $1,000 | Research payment | Cash or cash equivalent | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-P | 2022 | |
| 2022-12-07 | Gilead Sciences, Inc. | $693 | Research payment | Cash or cash equivalent | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-P | 2022 | |
| 2022-12-05 | Incyte Corporation | $361 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2022 | |
| 2022-12-05 | Genentech, Inc. | $295 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2022 |
| 2022-12-03 | Merck Sharp & Dohme LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-12-02 | Merck Sharp & Dohme LLC | $32,733 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-01 | ABBVIE INC. | $4,250 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allog | 2022 |
| 2022-12-01 | Janssen Research & Development, LLC | $2,316 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-12-01 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-12-01 | Janssen Research & Development, LLC | $1,320 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-12-01 | Janssen Research & Development, LLC | $112 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-11-28 | Kite Pharma, Inc. | $2,685 | Research payment | Cash or cash equivalent | Tecartus Drug, CELLT | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma | 2022 |
| 2022-11-25 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit | 2022 | |
| 2022-11-24 | ABBVIE INC. | $2,000 | Research payment | Cash or cash equivalent | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod | 2022 | |
| 2022-11-24 | ABBVIE INC. | $1,360 | Research payment | Cash or cash equivalent | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod | 2022 | |
| 2022-11-24 | Janssen Research & Development, LLC | $904 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-11-23 | Celgene Corporation | $18,432 | Research payment | Cash or cash equivalent | TRANSCEND 3L+ CLL- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Ch | 2022 | |
| 2022-11-23 | TRILLIUM THERAPEUTICS USA, LLC | $5,000 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2022 | |
| 2022-11-23 | Daiichi Sankyo Inc. | $2,714 | Research payment | Cash or cash equivalent | ENHERTU Drug, ONCOLOGY | DS-8201-A-U204 | 2022 |
| 2022-11-23 | Regeneron Pharmaceuticals, Inc. | $2,316 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2022 | |
| 2022-11-23 | Daiichi Sankyo Inc. | $2,316 | Research payment | Cash or cash equivalent | ENHERTU Drug, ONCOLOGY | DS-8201-A-U204 | 2022 |
| 2022-11-23 | Alkermes, Inc. | $1,993 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2022 | |
| 2022-11-23 | TRILLIUM THERAPEUTICS USA, LLC | $1,674 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2022 | |
| 2022-11-23 | Regeneron Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2022 | |
| 2022-11-23 | Regeneron Pharmaceuticals, Inc. | $1,320 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2022 | |
| 2022-11-23 | Daiichi Sankyo Inc. | $1,320 | Research payment | Cash or cash equivalent | ENHERTU Drug, ONCOLOGY | DS-8201-A-U204 | 2022 |
| 2022-11-23 | EMD Serono, Inc. | $476 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-11-23 | Regeneron Pharmaceuticals, Inc. | $442 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | PHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN | 2022 |
| 2022-11-23 | Alkermes, Inc. | $250 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2022 | |
| 2022-11-23 | Takeda Pharmaceuticals U.S.A., Inc. | $215 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2022 |
| 2022-11-23 | Regeneron Pharmaceuticals, Inc. | $115 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | PHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN | 2022 |
| 2022-11-23 | Alkermes, Inc. | $46 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2022 | |
| 2022-11-22 | Takeda Pharmaceuticals U.S.A., Inc. | $2,946 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2022 | |
| 2022-11-22 | Janssen Research & Development, LLC | $347 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-11-22 | Janssen Research & Development, LLC | $136 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-11-21 | Merck Sharp & Dohme LLC | $35,500 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol Paclitaxel HM30181A in | 2022 |
| 2022-11-21 | E.R. Squibb & Sons, L.L.C. | $4,476 | Research payment | Cash or cash equivalent | Ph I/II mono (lag3) vs combo (lag3 + nivo) (solid tumors) | 2022 | |
| 2022-11-18 | National Marrow Donor Program | $5,500 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with C | 2022 | |
| 2022-11-18 | National Marrow Donor Program | $2,304 | Research payment | Cash or cash equivalent | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administ | 2022 | |
| 2022-11-18 | Pharmacyclics LLC, an AbbVie Company | $1,000 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | 2022 |
| 2022-11-18 | Pharmacyclics LLC, an AbbVie Company | $831 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | 2022 |
| 2022-11-18 | Pharmacyclics LLC, an AbbVie Company | $80 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | 2022 |
| 2022-11-17 | Daiichi Sankyo Inc. | $6,175 | Research payment | Cash or cash equivalent | ENHERTU Drug, ONCOLOGY | DS-8201-A-U204 | 2022 |
| 2022-11-17 | Regeneron Pharmaceuticals, Inc. | $4,541 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2022 | |
| 2022-11-17 | Janssen Research & Development, LLC | $2,926 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-11-17 | Genentech, Inc. | $633 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | POLARIX | 2022 |
| 2022-11-17 | Bayer Healthcare Pharmaceuticals Inc. | $418 | Research payment | Cash or cash equivalent | Xofigo Drug, Oncology | Long Term follow up with Xofigo | 2022 |
| 2022-11-17 | Janssen Research & Development, LLC | $72 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-11-17 | Alkermes, Inc. | $13 | Research payment | In-kind items and services | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2022 | |
| 2022-11-16 | Janssen Research & Development, LLC | $4,333 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-11-16 | BeiGene, Ltd. | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho | 2022 | |
| 2022-11-16 | BeiGene, Ltd. | $1,360 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho | 2022 | |
| 2022-11-16 | Genentech, Inc. | $325 | Research payment | Cash or cash equivalent | Drug | PHASE III IPATASERTIB PLUS ABIRATERONE IN MCRPC 1ST LINE | 2022 |
| 2022-11-16 | BeiGene, Ltd. | $200 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho | 2022 | |
| 2022-11-16 | Exelixis Inc. | $198 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2022 |
| 2022-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2022 |
| 2022-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $990 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2022 |
| 2022-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $660 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2022 |
| 2022-11-15 | Genentech, Inc. | $90 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2022 |
| 2022-11-14 | CSL Behring | $2,160 | Research payment | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With | 2022 |
| 2022-11-11 | Exelixis Inc. | $3,069 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-11-11 | Exelixis Inc. | $2,038 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-11-11 | Exelixis Inc. | $2,038 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-11-11 | Exelixis Inc. | $660 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-11-10 | TRILLIUM THERAPEUTICS USA, LLC | $1,990 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2022 | |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $14,000 | Research payment | Cash or cash equivalent | A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo | 2022 | |
| 2022-11-09 | Merck Sharp & Dohme LLC | $6,060 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2022 |
| 2022-11-09 | SEAGEN INC. | $5,000 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-CD70 in Myeloid Malignancies | 2022 | |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $4,760 | Research payment | Cash or cash equivalent | A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo | 2022 | |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $4,000 | Research payment | Cash or cash equivalent | A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo | 2022 | |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo | 2022 | |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $2,040 | Research payment | Cash or cash equivalent | A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo | 2022 | |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With an Intravenous PD-1-Blocking Antibo | 2022 | |
| 2022-11-09 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or | 2022 |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $600 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | PHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN | 2022 |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | PHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN | 2022 |
| 2022-11-09 | Regeneron Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | PHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN | 2022 |
| 2022-11-09 | Genentech, Inc. | $200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2022 |
| 2022-11-08 | Genentech, Inc. | $14,000 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2022 |
| 2022-11-08 | Genentech, Inc. | $4,760 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2022 |
| 2022-11-08 | Regeneron Pharmaceuticals, Inc. | $3,536 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-11-08 | Genentech, Inc. | $2,040 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2022 |
| 2022-11-08 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2022 |
| 2022-11-08 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2022 |
| 2022-11-08 | Bayer Healthcare Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | Xofigo Drug, Oncology | Long Term follow up with Xofigo | 2022 |
| 2022-11-08 | Regeneron Pharmaceuticals, Inc. | $367 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-11-08 | Regeneron Pharmaceuticals, Inc. | $117 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
The latest 200 records of 1,135.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments